Sharekhan optimistic on Cadila Healthcare stock's prospects; recommends a BUY with price target of Rs 720
Brokerage firm Sharekhan says that Cadila Healthcare said that the company is making concentrated efforts to build a strong presence in areas of complex generics, injectable, and specialty portfolios in the US, which offer strong growth potential, which could unfold over the medium to long term. It recommends a buy on this stock with a target price of Rs 720
Cadila has been significantly progressing on the COVID-related treatments with Virafin (Pegylated Interferon alpha-2b) getting a restricted emergency approval for treating COVID-19 patients: Reuters